Emergent BioSolutions Receives FDA Approval Extending Shelf Life of BioThrax (Anthrax Vaccine Adsorbed) to 4 Years
ROCKVILLE, Md.--(BUSINESS WIRE)--Jun 10, 2009 - Emergent BioSolutions Inc. (NYSE:EBS) announced today that its flagship product, BioThrax (Anthrax Vaccine Adsorbed), has been granted a shelf life extension from 3 to 4 years by the U.S. Food and Drug Administration (FDA). Based on this approval,...
New Drug Approvals (FDA) · More like this

Emergent BioSolutions Announces That the Final Phase II Clinical Study Results for Typhoid Vaccine Reaffirms Clinical Endpoints Met; Immune Response Seen in 97% of Treated Subjects
...from a recently completed, randomized, placebo-controlled, blinded Phase II clinical study reaffirmed that its single-dose, drinkable typhoid vaccine candidate was highly immunogenic and well-tolerated with an acceptable safety profile in the population studied. For the study, a total of 151...
Clinical Trial Results (FDA) · More like this

Emergent BioSolutions' Typhoid Vaccine Candidate Achieves Endpoints in Phase II Clinical Study
...results from a recently completed, randomized, placebo-controlled Phase II clinical study demonstrated that its single-dose, drinkable typhoid vaccine candidate achieved the study endpoints for safety and immunogenicity. In this clinical study, which recruited children between 5 and 14 years of...
Clinical Trial Results (FDA) · More like this

Having trouble finding what you want?

• Try browsing our A-Z List of Drug Names or our Medical Encyclopedia.
• Try posting your query on the Drugs.com Community Discussion Boards
• Drug Interactions Checker provides detailed information on drug-drug and drug-food interactions.
• Pill Identifier will help you identify an unknown pill by imprint code or shape/color.
• Image Search is helpful if you want to know what a certain pill looks like.
• News, FDA Approvals or In The Pipeline may help if the drug you are looking for is a new drug.